Fate Therapeutics announces pricing of public offering of common stock
Fate Therapeutics announced pricing of an underwritten public offering of 8,600,000 shares of its common stock at a public offering price of $17.50 per share for gross proceeds of $150.5 million. Fate Therapeutics granted underwriters a 30-day option to purchase an additional 1,290,000 shares. September 12, 2019